Articles tagged with Human Immunodeficiency Virus
Pharmacokinetic data suggest that 908 can be co-administered with Maalox TC or Zantac without dose adjustments. Co-administration with Lipitor increased ATO exposure but did not affect 908 PK.
An interim analysis of a study comparing TDF to EFV in combination with 3TC + ABC found that the TDF arm had a higher rate of virologic non-response. The study included 194 patients and showed that VL <400 copies/mL was achieved in 49% of TDF subjects, compared to 90% of EFV subjects.
A study suggests that new HIV treatments can lead to a decrease in people's concerns about the disease, resulting in increased transmission rates. Researchers believe that health professionals should address this issue by revamping prevention messages and programs.
The study found that the three-drug combination of abacavir, lamivudine, and efavirenz provided a potent antiretroviral response over 48 weeks. Subjects in the ABC/3TC/EFV group had a significantly better immunologic response compared to those in the ZDV/3TC/EFV group.
A recent study published in Johns Hopkins Medicine found that giving one dose of nevirapine to HIV-positive mothers during labor and their newborns reduced transmission by 41 percent. The simple regimen has the potential to prevent hundreds of thousands of new infections every year.
A long-term study found that nevirapine sustained a 41% reduction in HIV infection risk compared to azidothymidine (AZT) in infants born to breastfeeding mothers. The regimen showed significant cost savings, approximately 70 times less than AZT treatment.
Researchers found that total lymphocyte count and hemoglobin concentration decline rapidly in individuals who develop AIDS, with over 77% of study participants exhibiting these declines. This finding offers an alternative to current HIV diagnosis methods, which require expensive technology and equipment.
A genetically engineered strain of lactobacillus could significantly inhibit HIV infection in humans, offering a safe and long-lasting way to protect women. The research uses naturally colonizing bacteria to block and inactivate viruses before they reach host cells.
Researchers have found that a one-step HIV test is the least expensive option, costing nearly $82 per person compared to two-step methods. The new method provides same-day results for both HIV-positive and negative clients, reducing waste and costs associated with return clinic visits.
Researchers at University at Buffalo's Laboratory for Antiviral Research are conducting a comprehensive study to measure concentrations of drugs and analyze their pharmacogenetic basis. The goal is to understand the net effect of antiretroviral drugs on other pharmaceuticals taken by HIV patients.
Researchers found that structured treatment interruption in people with multidrug-resistant HIV led to more HIV-related complications and poorer immune response. The study suggests that continuing therapy guided by HIV drug resistance testing is a better approach for this group of HIV-infected individuals.
Researchers suggest that heightening immune response against human proteins in viral envelope could prevent HIV infection, offering a potential solution for reducing transmission rates. This approach, called alloimmunization, has the advantage of working against all strains of HIV and other retroviruses.
Dale J. Kempf, Daniel W. Norbeck, and Hing L. Sham receive award for developing Kaletra, the first HIV protease inhibitor approved for use in children as young as six months old.
A randomized, controlled study involving medical marijuana found no harmful changes in HIV virus levels or immune system function in patients with HIV. Participants experienced weight gain, but no change in their undetectable status.
A study of 181 sexually active Zimbabwean women found that diaphragms can be used without a partner's knowledge to prevent HIV transmission. The researchers suggest that this method could provide an additional tool for HIV prevention, particularly for women who do not have access to condoms or other forms of protection.
A new computer-based system, ACASI, was tested with Zimbabwean women, yielding more accurate data on key HIV risks. The tool helped overcome cultural issues and social desirability bias in face-to-face interviews.
A new UCLA study suggests that coronary heart disease may be accelerated in younger HIV-infected people. The research found that the rate of coronary heart disease in young HIV-positive men and women was significantly higher than in their HIV-negative counterparts.
A study found that HIV treatment costs increased significantly between 1995 and 2001, driven by the use of highly active antiretroviral therapy (HAART). Despite this, overall medical care costs remained relatively stable during the same period.
The FDA has approved a safety trial for the second component of a three-part HIV vaccine developed at St. Jude Children's Research Hospital. The vaccine aims to overcome viral diversity with a multi-envelope approach, and includes three components: DNA, genetically modified vaccinia virus, and purified HIV envelope protein.
NC State statisticians Drs. Anastasios Tsiatis, Marie Davidian and Marc Genton have won a $1.125 million NIH MERIT Award for their work on statistical methodology in designing complex HIV clinical trials. Their research aims to develop sophisticated designs that can handle the variability of patients' responses to treatment.
A research team led by Nathaniel Landau identified the interaction between HIV's Vif protein and APOBEC3G. The study found that mice have a similar antiviral protein that can block HIV replication due to its inability to recognize human proteins.
Researchers found that rare variations of HLA-A and HLA-B genes can protect against HIV. The study, which analyzed data from 996 HIV-infected men in Chicago, suggests that these genetic variants may be used to develop targeted AIDS vaccines.
Risk experts address communication challenges in public health and policy contexts, discussing factors like perception, information quality, and industry influence. Effective risk communication is crucial for public health decisions and policy-making.
Researchers at TSRI describe an unusual antibody configuration that effectively neutralizes HIV by binding to sugars on its surface. This breakthrough could lead to designing an effective AIDS vaccine by stimulating the human immune system to produce similar broadly neutralizing antibodies.
Scientists have determined the structure of the 2G12 antibody, which neutralizes HIV by binding to sugars on its surface. The antibody's unique structure could provide a template for designing an antigen that triggers the body to produce it, potentially leading to an HIV vaccine.
Researchers have identified a molecular fingerprint unique to individuals with HIV-associated dementia (HAD), suggesting the potential development of a simple blood test for its diagnosis. The study used proteomics to analyze protein patterns in patients and found correlations between certain proteins and HAD.
India's HIV prevalence rate is less than 1 percent, but a looming pandemic on the horizon due to shifting demographics and changing cultural values. The researchers recommend targeted prevention programs for high-risk groups, such as prostitutes and men who have sex with men, and offer circumcision as an additional avenue of prevention.
Researchers analyzed lipid levels of HIV patients before and during HAART and found that average total and LDL cholesterol levels remained stable over three years. After initiation, cholesterol levels rose but returned to pre-infection levels after a year. However, triglyceride and HDL levels were higher than in similar-aged men.
A study found that HIV-positive individuals are more likely to engage in undisclosed, unprotected sex, particularly with gay or bisexual men. The lack of disclosure is attributed to high prevalence and awareness of HIV in the gay community, as well as stigma surrounding HIV positivity.
Researchers challenge assumption that poverty is a risk factor for non-adherence to HIV medication regimens, citing high treatment adherence rates in South African studies. The editorial argues that delivery systems may compromise confidentiality and risk stigmatization if not based on clear evidence.
Researchers found that CEM15 renders HIV dead by altering DNA, causing mutations and preventing replication. The virus can subvert this system, enabling it to make numerous mutations and evade the host's defense.
The study found that many HIV-infected gay and bisexual men tailor their sexual activity to reduce the risk of HIV transmission to casual partners they do not disclose to. Barriers to disclosure include stigma and fears of rejection, suggesting that public health efforts must address these concerns.
A study by Northwestern University found that juvenile detainees aged 10-18 engage in significantly higher rates of HIV-risk behaviors, with 95% exhibiting multiple sexual and drug risks. Boys were more likely to engage in riskier behaviors, while girls aged 16+ were more active sexually.
Designing molecules to block HIV receptors could lead to more effective and safer treatments. The approach has the potential to be orders of magnitude more effective than existing treatments, with fewer side effects.
A study by Mayo Clinic researchers found that a specific Vpr mutation is associated with long-term nonprogressive HIV infection, where infected individuals exhibit preserved immune function. The discovery suggests a potential therapeutic opportunity for Vpr inhibitors to reduce T cell death during HIV infection.
Researchers identify a helpful gene mutation in the Vpr gene of long-term nonprogressive HIV patients, which impairs the HIV virus' cell-killing machinery. The presence or absence of this mutation may play a central role in determining which patients develop fatal AIDS.
HIV-infected individuals with a history of alcohol problems who consume moderate or at-risk amounts of alcohol have higher viral loads and lower CD4 cell counts compared to non-drinkers. Heavy alcohol consumption is linked to increased disease progression, nonadherence to treatment, and worsened comorbid conditions.
A study of over 300 HIV patients found that 32% reported better life after diagnosis, with fewer worries about finances or disclosure. Patients who said life was better expressed more optimism and participated in non-organized religious activities.
Dr. Sundquist's research has identified key cellular proteins necessary for HIV release, providing potential new targets for anti-HIV drugs. By altering the structure of these proteins or blocking their interaction with HIV, future treatments may slow or halt infection.
A study by Johns Hopkins Bloomberg School of Public Health reveals that Pakistani and Afghan drug users are at high risk of HIV due to limited knowledge and risky behaviors. The research highlights the need for interventions such as needle exchange programs and drug treatments to prevent blood-borne infections.
The region is facing a major public health crisis with an estimated 1 million individuals already infected, mostly through injecting drug use. Improved measures are urgently needed to prevent further HIV spread and protect vulnerable populations.
HIV-1 uses a unique 'glycan shield' mechanism to evade antibody attack, continuously changing large sugar molecules on its surface. This allows the virus to outsmart the immune system and escape elimination.
Researchers are developing nanotech decoys that can stick to the HIV virus and prevent it from entering human cells. The study focuses on the binding of gp120 protein to GalCer molecules in cell membranes.
A study led by Dr. Debra Bekerian found young gay men are anxious and depressed, with many unaware of their HIV status. Trauma may have a protective effect on health behavior, and the report suggests improving health messages using the internet could help reduce unsafe sexual practices.
Researchers found that HIV patients develop strong antibody responses against the virus, but these antibodies fail to keep pace with the virus's constant mutation process. This study sheds light on the complex dynamics between the immune system and HIV, highlighting potential avenues for vaccine development.
A study in Alberta found that mandatory reporting of HIV infection did not significantly impact testing rates among the general population. However, an opt-out prenatal screening policy resulted in a dramatic increase in female tests, suggesting that fear of receiving a positive test may be a more significant deterrent to testing.
The study found increased condom use in intervention groups but no impact on HIV incidence, highlighting the need for more effective STI and behavioral interventions to control HIV in Uganda. The researchers emphasize the importance of rigorous evaluation and development of promising interventions.
A recent study analyzed data from the Veterans Affairs HIV patient population between 1993 and 2001 and found a sharp decline in overall death rates among patients. Despite concerns about vascular disease as a side effect of HAART, the study suggests that these drugs may not increase the risk of this condition.
A recent study found that 78% of HIV-positive N.C. men and women prisoners had unprotected sex with their main partner in the year before imprisonment. Upon release, 26% admitted to having sex without condoms with that same person within a day or two.
Researchers found that HIV protease inhibitors directly promote atherosclerosis in mice by inducing changes in macrophages. A commentary article proposes a mechanism and suggests ways to disrupt this process. The study has significant implications for the long-term use of these drugs in managing chronic HIV infection.
A new vaccine based on a chimpanzee adenovirus has shown promise against HIV by inducing a powerful T-cell-based immune response in mice. The vaccine avoids the issue of pre-existing immunity seen with human adenovirus vaccines.
HIV patients who use self-distraction techniques or drugs to cope with stress report reduced energy levels and social activity limitations. Pain affects daily activities, work performance, and school performance.
A study in rural Uganda found that domestic violence affects nearly half of women, with those whose partners consume alcohol facing a higher risk. The research highlights the connection between domestic violence and HIV risk, suggesting that addressing domestic violence may be crucial to preventing HIV transmission.
The NIH has awarded nearly $8 million to the University of Pittsburgh and Magee-Womens Research Institute to develop a microbicide barrier to prevent HIV transmission in women. The project aims to create a safe and effective way for women to protect themselves against sexually transmitted infections, including HIV.
A pilot study of HIV patients in New York City found that those with social support were more likely to take their medications consistently. The study highlights the importance of social contact in overcoming adherence challenges for individuals living with HIV.
A study of 137 adults with HIV found that simplifying their medication regimens can significantly improve adherence, particularly for those with memory and attention problems. The study suggests a two-way relationship between missed doses and disease progression, highlighting the need for more effective treatment strategies.
Researchers have successfully created a delivery system using a vehicle derived from HIV itself to introduce synthetic siRNAs into human cells. This approach aims to prevent HIV infection by knocking out the CCR5 receptor, which is found on T-cells and plays a role in immune function.
Researchers at UIC provided the first images of HIV in living cells, revealing how the virus enlists host assistance to wreak havoc on the body's defenses. The visualization, which took four years to develop, shows HIV particles hitching a ride aboard dynein, a molecular motor, and crossing the microtubular highway to reach the nucleus.
Researchers discovered that an individual could become infected with two closely related strains of HIV, highlighting the challenges in creating a vaccine against this highly variable virus. The study found that a hypothetical vaccine against one strain may not protect against other closely related strains.
A UCSF study of 239 men who have sex with men found no cases of HIV transmission through receptive oral sex. The study contradicts previous case reports and confirms the probability of zero transmission for this activity.